Prana Biotechnology Ltd (PRAN)’s Financial Results Comparing With Sophiris Bio Inc. (NASDAQ:SPHS)

Prana Biotechnology Ltd (NASDAQ:PRAN) and Sophiris Bio Inc. (NASDAQ:SPHS) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prana Biotechnology Ltd N/A 0.00 N/A -0.66 0.00
Sophiris Bio Inc. 1 0.00 N/A -0.19 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Prana Biotechnology Ltd and Sophiris Bio Inc.

Profitability

Table 2 provides us Prana Biotechnology Ltd and Sophiris Bio Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Prana Biotechnology Ltd 0.00% 0% 0%
Sophiris Bio Inc. 0.00% 582.1% -40.2%

Analyst Recommendations

Recommendations and Ratings for Prana Biotechnology Ltd and Sophiris Bio Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Prana Biotechnology Ltd 0 0 0 0.00
Sophiris Bio Inc. 0 0 3 3.00

Competitively the average price target of Sophiris Bio Inc. is $4.83, which is potential 383.05% upside.

Insider and Institutional Ownership

Prana Biotechnology Ltd and Sophiris Bio Inc. has shares owned by institutional investors as follows: 3.61% and 7.7%. Insiders Comparatively, owned 0.85% of Sophiris Bio Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Prana Biotechnology Ltd 0% 0% 0% 0% 0% 0%
Sophiris Bio Inc. -1.98% 21.82% 10.61% -11.61% -65.26% 19.28%

Summary

Sophiris Bio Inc. beats Prana Biotechnology Ltd on 6 of the 7 factors.

Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of AlzheimerÂ’s: and that is in Phase IIa clinical trials for the treatment of HuntingtonÂ’s diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for ParkinsonÂ’s disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.